An In-depth review of Hexarelin – A Next Generation GHRP

Disclaimer-lotilabs-banner

An In-depth review of Hexarelin – A Next Generation GHRP

Clinical research using hexarelin is helping scientists understand the complexities of how the heart functions and the processes that lead to heart diseases, and eventually death. It has also opened doors to numerous possibilities, such as cardiac remodeling that seemed daunting in the past. Loti Labs is a USA based peptide and research company, and we stock USA made hexarelin for sale for research purposes only. We acknowledge the importance of using high-quality products and are strategically equipped to ensure you have the best peptides to make this happen. Hexarelin and peptides in general should only be handled by qualified professionals.

WHAT IS HEXARELIN

Hexarelin is a new synthetic growth hormone-releasing peptide (GHRP). It is also known as examorelin. It is a synthetic analog of ghrelin and is closely related to GHRP-6. It is more stable and more potent than ghrelin. It is made up of 6 amino acids, with the sequence (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2).

Hexarelin may be used in the lab to study the functions of ghrelin, which is made up of 28 amino acids and requires acylation to bind to the growth hormone secretagogue receptor 1a (GHS-R1a).

STRUCTURE OF HEXARELIN

Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2

Molecular Formula: C47H58N12O6

Molecular weight: 887 g/mol

CAS number: 140703-51-1

MECHANISM OF ACTION

Hexarelin acts through specific receptors at both the pituitary and the hypothalamic level to stimulate growth hormone release in animal test subjects. It is thought to affect the release of the growth hormone through a phospholipid-dependent protein kinase (PKC) signaling. It mimics the action of ghrelin by binding to the growth hormone secretagogue receptor 1a (GHS-R1a). It also binds to and activates the cardiac receptors CD36.

Like other GHRPs, hexarelin possesses significant prolactin and adrenocorticotropin (ACTH) cortisol-releasing activity. However, plasma glucose, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, and insulin-like growth factor 1 are not affected by hexarelin administration.

HEXARELIN SIDE EFFECTS

Some of the common side effects observed with hexarelin are because of its effect on adrenocorticotropic hormone (ACTH), cortisol, and prolactin. These include:

  • Lethargy
  • Water retention
  • Low libido
  • Tingling or numbness in the hands and feet
  • Carpal tunnel-like symptoms in the wrist
  • Increased cortisol levels
  • Increased prolactin levels
  • A decrease in insulin sensitivity
  • Excessive sleepiness

LOOKING FOR WHERE TO BUY PEPTIDES

Hexarelin can be purchased from Loti Labs. It is important to buy peptides which are USA-made to ensure the integrity of your research. Hexarelin sold from Loti Labs is tested through HPLC and Mass spectrometry to ensure quality. Hexarelin is commonly sold in 2mg vials. It is available in lyophilized powder form.

References

National Center for Biotechnology Information. PubChem Database. Examorelin, CID=6918297, https://pubchem.ncbi.nlm.nih.gov/compound/Examorelin (accessed on Mar. 10, 2020)

Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253–258. doi:10.11909/j.issn.1671-5411.2014.03.007

Bellone J, Bartolotta E, Sgattoni C, et al. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and adults but not in prepubertal children and elderly subjects. J Endocrinol Invest. 1998;21(8):494–500. doi:10.1007/BF03347334

Arvat E, Ramunni J, Bellone J, et al. The GH, prolactin, ACTH, and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations. Eur J Endocrinol. 1997;137(6):635–642. doi:10.1530/eje.0.1370635

Imbimbo, B.P., Mant, T., Edwards, M. et al. Growth hormone-releasing activity of hexarelin in humans. Eur J Clin Pharmacol 46, 421–425 (1994). https://doi.org/10.1007/BF00191904

Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445–460. doi:10.1530/eje.0.1360445

Share this post